Goldman Sachs’s Intellia Therapeutics NTLA Stock Holding History

Goldman Sachs’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,200	Closed	-$152K	–	6557
2025 Q2	$152K	Hold	16,200	–	–	﹤0.01%	5733
2025 Q1	$115K	Buy	+16,200	New	+$164K	﹤0.01%	5758
2022 Q1	–	Sell	-15,000	Closed	-$1.77M	–	6805
2021 Q4	$1.77M	Buy	+15,000	New	+$1.88M	﹤0.01%	4346
2021 Q3	–	Sell	-34,000	Closed	-$5.5M	–	6428
2021 Q2	$5.5M	Buy	34,000 +30,000	+750%	+$2.34M	﹤0.01%	3258
2021 Q1	$321K	Buy	+4,000	New	+$268K	﹤0.01%	5397

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Goldman Sachs's NTLA Position: Q2 2026 in Review

Goldman Sachs increased its Intellia Therapeutics (NTLA) stake by 39% in Q2 2026, buying an estimated $8.9M and bringing the position to 2,264,471 shares worth $38.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Goldman Sachs first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $161M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Goldman Sachs held 2,264,471 shares of Intellia Therapeutics worth $38.3M as of Q2 2026.
Goldman Sachs bought 636,230 Intellia Therapeutics shares in Q2 2026, an estimated $8.9M.
Intellia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2037 holding.
Goldman Sachs first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
Goldman Sachs's Intellia Therapeutics position peaked at $161M in Q2 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.